Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPAH-trial
2024-518551-37-00Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) comparing Dapagliflozin (Forxiga) with Placebo (2 arms). Primary endpoint: Change in maximum oxygen consumption (VO2 max). Started Oct 2024; status: completed.
02
Drugs
dapagliflozin
03
Conditions
pulmonary arterial hypertension (PAH)chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on 2024-518551-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518551-37-00.